Research Article

Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms

Zhengjie Shen (1,2,3), Yongjuan Gu (1), Ruiyang Jiang (3,4), Heya Qian (1), Siyuan Li (1), Lixian Xu (1), Wenzhe Gu (2), and Yun Zuo (1)

(1) The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang 215600, China
(2) Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang 215600, China
(3) Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing 210023, China
(4) Nanjing University of Chinese Medicine, Nanjing 210023, China

Correspondence should be addressed to Wenzhe Gu; zjgzy088@njucm.edu.cn and Yun Zuo; zuoyun1@163.com

Received 12 August 2022; Revised 12 September 2022; Accepted 29 September 2022; Published 12 October 2022

Academic Editor: Lubna H. Tahtamouni

Copyright © 2022 Zhengjie Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Purpose. Breast cancer ranks first in the incidence of female tumors. Triple-negative breast cancer (TNBC), one type of breast cancer, is more aggressive and has a worse prognosis. Demethylzeylasteral (T-96) is isolated from Tripterygium wilfordii Hook F. Our previous study found that T96 could inhibit TNBC invasion via suppressing the canonical and noncanonical TGF-β signaling pathways. However, the antitumor effects and mechanisms of T-96 on TNBC have not been studied. This study is aimed at investigating the antitumor effect and mechanism of T-96 on breast cancer.

Experimental approach. MTT assay, Live and Dead cell assay, and TUNEL were used to observe the antitumor effect of breast cancer cells treated with T-96. siRNA of LSD1, Co-IP, and molecular docking were used to explore the direct target and mechanism of T-96. Subcutaneous murine xenograft models were used to detect the efficacy of T-96 antitumor activity in vivo.

Key Results. T-96 was more susceptible to inducing the apoptosis of highly metastatic TNBC cell lines (SUM-1315). An abnormal level of histone methylation is a crucial characteristic of metastatic cancer cells. LSD1 is a histone demethylase. We found that T-96 could significantly decrease the protein expression of LSD1, increase its target protein PTEN expression and enhance histone methylation. T-96 could also down-regulate the PI3K/AKT signaling pathway, which could be blocked by PTEN. Knockdown of LSD1 by siRNA blocked the pharmacological activity of T-96. And the molecular docking predicted T-96 processed a affinity toward LSD1 through hydrogen bonding. Finally, T-96 was evaluated in a murine xenograft model of SUM-1315 cells. And T-96 could significantly inhibit tumor growth without showing marked toxicity.

Conclusions & Implications. The results illustrated that T-96 exerted antitumor activity in highly metastatic TNBC by inactivating the LSD1 function.

1. Introduction

According to the global cancer statistics 2020, breast cancer has been the most commonly diagnosed cancer and the leading cause of cancer death in women. It is estimated that in 2020 there would be 2.26 million new cases (11.7% of total cases) and 684,996 new deaths (6.9% of total cases) in 36 cancers [1]. Triple-negative breast cancer (TNBC) accounting for approximately 15% of invasive breast cancers, is the most aggressive subtype, which has the characteristic of loss of expression of estrogen receptor (ER) and progesterone receptor (PR) and does not have amplification of the epidermal growth factor receptor 2 (ERBB2). Because of the absence of antihormone and anti-ERBB2 targeted therapies, chemotherapy has been the first-line therapeutic option for TNBC patients. But the clinical response to chemotherapy is limited and associated with toxicity [2, 3]. Therefore, developing novel drugs and therapies is essential for TNBC.

Epigenetics, which involves noncoding-RNAs, histone modifications, and DNA methylation, is the study of potentially heritable changes in gene expression without changes in the DNA sequences or genotype. [4–6] Histone
methylation, a process in that methyl group is transferred to amino acids of histone proteins, has been associated with cancer, cardiovascular disease, and Alzheimer’s disease [7–9]. Histone methyltransferases and histone demethylases, which methylate and demethylate protein lysine and arginine residues, have crucial roles in the control of histone methylation regulation [10, 11]. So, this family of enzymes plays key roles in normal physiology and human diseases and could be novel, chemically tractable potential therapeutically targets for drug discovery.

Lysine (K)-specific demethylase 1A (LSD1) is the first discovered histone lysine demethylase and is encoded by the KDM1A gene [12]. LSD1, which is a flavin-dependent monoamine oxidase, can demethylate mono- and dimethyl groups on the H3K4 for suppressing gene expression, or convert di-methylated H3K9 to mono- and unmethylated H3K9 for increasing gene expression [13, 14]. This protein matters in embryonic stem cell self-renewal and tissue-specific differentiation, which as well as regulates other pathological processes [15, 16]. LSD1 is also thought to have a vital function in various tumor biological processes, such as proliferation, cell survival, and epithelial-to-mesenchymal transition (EMT). And the higher expression of LSD1 indicates poorer outcomes [17–19]. Therefore, the inhibition of LSD1 may be a promising drug target for cancer therapy [20, 21].

*Tripterygium wilfordii* Hook F. (TWHF) is a traditional Chinese herbal, which is widely distributed in China, Japan, and Korea. Demethylzyelylasteral (T-96), the most important constituent of TWHF, is extracted from the TWHF whole plant or peeled wood parts [22]. And some research has demonstrated that T-96 has an obvious immunomodulatory effect and antitumor activity, such as suppressing inflammation, inhibiting tumor growth, enhancing chemosensitivity, etc. [23–25]. It has been reported that T-96 could also suppress the tumorigenicity induced by liver cancer stem cells by inhibiting H3 histone lactylation, which indicates that the antitumor effects of T-96 are related to epigenetic molecules [26]. So, we hypothesize that T-96 has an antitumor effect on TNBC cells through LSD1-mediated histone modification. In the previous study, we found that T-96 could reverse EMT and inhibit the invasion of TNBC cells by suppressing the TGF-β signaling pathway [27]. However, its antitumor effects and mechanisms have not been thoroughly studied. In this study, we investigated T-96’s antitumor activity on two breast cancer cell lines, SUM-1315 cell line, a highly metastatic and *BRCA1* mutant TNBC cell line, and MCF-7 cell line, a lowly metastatic and ER-positive breast cancer cell line. And we also explored whether T-96’s anti-tumor mechanism is through LSD1-mediated histone modification.

2. Materials and Methods

2.1. Reagents and Materials. Dulbecco’s modified Eagle’s medium (DMEM), Penicillin-Streptomycin (10,000 U/mL), fetal bovine serum (FBS), and L-Glutamine (200 mM) were obtained from Thermo Fisher Scientific Inc., US. MTT and DMSO were obtained from Sigma Chemical Co., US. All antibodies were obtained from Abcam Co., US. T-96 was purchased from BioBioPha Co., China.

2.2. Cell Lines and Cell Culture. Human breast cancer cell lines SUM-1315 and MCF-7 were cultured in DMEM supplemented with 10% FBS, Penicillin-Streptomycin (100 U/mL), and L-Glutamine (2 mM) at 37°C with 5% CO₂ in a humidified incubator. Cells were digested with 0.5 mL 0.25% trypsin for 1-3 minutes at 37°C. And 2 mL complete medium was added to neutralize the trypsin. The cells were used during their logarithmic growth phase. [28]

2.3. Cell Viability Assay. Cell viability was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. First, we seeded the cells at a concentration of 5×10³ cells/well in a 96-well plate for 24 h. T-96 was dissolved in DMSO and prepared to a parent solution concentration of 100 mM. And then, the cells were grown in different concentrations of T-96 (1, 2, 4, 8, 12 μM) for 24 h or 48 h. Cisplatin (CP, 8 μM) was used as a positive control group. After being treated with T-96 or CP for 24 h or 48 h, the 10 μL MTT solutions (5 mg/ml) was added to each well and incubated for 4 h. 100 μL DMSO was added to each well to solute the crystal. Absorbance was measured by the plate reader at a wavelength of 492 nm. [29]

Live and Dead cell assay was also used to detect the cell viability. The Live and Dead cell assay staining solution is a mixture of two fluorescent dyes that differentially label live and dead cells. The Live cell dye labels intact, viable cells green. The Dead cell dye labels cells with compromised plasma membranes red. A Live and Dead staining kit (Yeasen, China) was used to assess the antitumor activity of T-96 on SUM-1315 cells. After being treated with or without T-96 for 48 h, the cells were collected through a cell scraper. Cells were washed, and after centrifugation, a cell suspension of density 10⁵ cells/mL was made with 1× Assay Buffer. Add 100 μL staining reagent to 200 μL cell suspension, incubated for 15 min at 37°C, and then be observed under fluorescence microscopy (Nikon, Japan).

2.4. Transient Transfection. The cells were inoculated in six-well plates. LSD1-specific siRNA (sc-60970, Santa Cruz, US) or nontarget-specific control siRNA (sc-37007, Santa Cruz, US) was transiently transfected by Invitrogen™ Lipofectamine 3000 transfection reagent, according to instructions provided with the reagent. [30] After that, the cells were treated with T-96 and cultured for 48 h, and the proteins were harvested for subsequent studies.

2.5. Coimmunoprecipitation (coIP) Assay. In the standard Co-IP assay, cells were lysed in RIPA buffer (Beyotime, China). The cell lysates were clarified by centrifugation at 14,000×g for 10 minutes, and the supernatant was collected. After removing the bottom precipitate, 2 μg of the primary antibody was added to 1 mg of clarified total cell lysates and incubated overnight at 4°C. The next day, Protein A-agarose beads (Santa Cruz, US) were added and incubated for 2 h. Then, the beads were washed three times with ice-cold RIPA buffer, followed by adding 1× SDS loading buffer to resuspend. After microcentrifugation for 30 s, the sample
is heated to 96°C for 10 min and centrifuged for 1 min at 14,000 x g. [31, 32]

2.6. Extract the Nuclear Protein. The nuclear protein was prepared in accordance with the protocol from a Nuclear Extraction Kit (Beyotime, China). Remove the growth medium and wash cells with PBS, after removing the PBS, scrap off cells with a cell scraper. Cells were harvested by centrifugation. Vortex for 5 seconds, the cell precipitate was completely suspended and dispersed. Put the sample on ice for 5 min. Cytoplasmic protein extraction reagent B was added, vortexed, and centrifuged, and the supernatant was removed to a new EP tube. For precipitation, the residual supernatant was completely aspirated and a nuclear protein extraction reagent supplemented with PMSF was added. After vortex and centrifugation, the supernatant was taken, which was the extracted nuclear protein.

2.7. Western Blot Analysis. After treatment with various concentrations of T-96 for 48 h, total cellular proteins were extracted by RIPA buffer, electrophoresed on 12% SDS-PAGE, and transferred to PVDF membrane by semidyriy apparatus for 35 min. The membrane was blocked and incubated with the primary antibody at recommended concentrations overnight at 4°C. Next day, the membrane was washed with PBS three times, and incubated with the secondary antibody for 1 h, and then the membrane was incubated with the ECL. Finally, the signals were detected by Tanon Western Blot System (Shanghai, China). [33]

2.8. Murine Models. All murine experiments were conducted under protocols approved by the Animal Care and Use Committee of Jiangsu Province Academy of Traditional Chinese Medicine. The nude mice were raised in an air-conditioned pathogen-free environment. SUM-1315 cells (1 x 10^7 cells) were injected subcutaneously into the right flank of the nude mice. When tumors became palpable, the mice were randomly divided into two groups and treated with T-96 (5 mg/kg) or vehicle (1% DMSO) in normal saline for 25 days. The body weight and tumor size were measured every 5 days. On the 25th day, all mice were sacrificed; the tumors and tissue were excised, and frozen inside a -80°C refrigerator for the next experiments.

2.9. Immunohistochemistry Assay. Tumor tissues were formalin-fixed, paraffin-embedded, and sectioned at 5 μm thick. Sections were deparaffinated and rehydrated, and endogenous peroxidase activity was blocked with 3.0%
H₂O₂. Then, Sections were incubated overnight with the primary antibody followed by the secondary antibody for 30 minutes. Staining was visualized using the DAB Kit (Keygentec, China). [34]

2.10. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) Assay. TUNEL staining of paraaffin-embedded tumor sections was performed according to protocols provided by the manufacturer (Roche Diagnostics, Mannheim Germany). Images were acquired with Nikon Microscope.

2.11. Immunofluorescent Assay. Tumor tissues were sectioned and analyzed by immunofluorescence as described [35]. Images were acquired with Nikon Microscope.

2.12. Docking Molecules. T-96 was drawn with Chemdraw 2014 and opened in Maestro 10.2. Then, the ligands were processed with the Ligand preparation protocol in Maestro 10.2. And LSD1 (PDB id: 2Z5U) was downloaded from PDB (http://www.rcsb.org/pdb) and opened by Maestro 10.2. The Glide docking protocol was adopted for the docking studies.

2.13. Statistical Analysis. Data were presented as mean ± SD and analyzed by SPSS 15.0 software, and all the raw data was carried out on the T-test. P < 0.05 was considered statistically significant.

3. Result

3.1. T-96 Selectively Kills Highly Metastatic Breast Cancer Cell Line. In Figure 1(a), MTT assays showed that T-96 induced cytotoxicity more effectively in the highly metastatic TNBC cell line (SUM-1315) than in the lowly metastatic breast cancer cell line (MCF-7). T-96 caused morphological changes in these breast cancer cells tested (Figure 1(b)). The SUM-1315 cell volume decreased, the intercellular junctions disappeared, and some cells shrank and became round. Significant changes were observed in the high-dose group (8 μM). Treatment of the SUM-1315 cell line with T-96 resulted in a significantly higher number of cell apoptosis compared with the MCF-7 cell line. So, compared with the lowly metastatic breast cancer cell line, T-96 displayed a preferential antiproliferative activity against the highly metastatic breast cancer cell line (SUM-1315). Thus, SUM-1315 was chosen as a model for further investigation of the antitumor activity and the underlying mechanisms of T-96.

3.2. T-96 Induces Apoptosis in SUM-1315 Cells. Live and Dead assay and Western Blotting assay demonstrated that T-96 reduced the viability of SUM-1315 cells in a concentration-dependent manner via apoptosis in Figure 2. By Live and Dead assay, compared with the control group, the number of green fluorescent cells significantly decreased and red fluorescence increased after T-96 treatment. We found that T-96 drastically induced cell death (Figure 2(a)). And next, the Western Blotting assay was used to detect apoptosis-related proteins expression, and we found that Bcl-2 and Bcl-xl, two antiapoptotic proteins, were significantly decreased in the treatment group. But Bax, a proapoptotic protein, was significantly increased in the treatment group (Figures 2(b) and 2(c)). These data indicated that the T-96-induced apoptosis was at least partially by modulating the expression of Bcl-2 family proteins.

3.3. T-96 Inhibits LSD1-Mediate Epigenetics Mechanism in SUM1315 Cells. Histone methylation, a covalent
postranslational modification (PTM) to histone proteins, plays a critical role in the regulation of chromatin structure, and its dynamics control several cellular processes such as proliferation, cell cycle, and programmed cell death [36–38]. Histone methyltransferases and demethylases are the major contributors to the establishment and maintenance of the level of different histone lysine methylations. So, they have been considered novel drug targets for cancer therapy [39]. LSD1, the first discovered histone lysine demethylase, is proposed to mediate the demethylation of H3K4me1/2 and H3K9me1/2 through a flavin adenine dinucleotide (FAD)-dependent amine oxidation reaction [40, 41]. LSD1 is highly expressed in various cancers and correlates with poor prognosis in patients [42, 43]. In breast cancer, LSD1 is highly expressed in ER-negative breast cancers and it has been proposed as a biomarker predicting aggressive biology [42].

Figure 1(a) showed that TNBC cells were more sensitive than ER-positive breast cancer cells to the growth-inhibitory effects of T-96 and implied that T-96 played an antitumor effect via inhibition of LSD1 function. And Western Blotting assay was employed to prove this hypothesis. In Figures 3(a) and 3(b), the result showed that T-96 decreased the protein expression of LSD1. Next, we found that T-96 increased the protein expression of PTEN, which was directly regulated by LSD1 [44]. And T-96 also enhanced the methylation level of H3K4me2 in Figures 3(c) and 3(d). PTEN was a natural inhibitor of the PI3K/AKT cell signal pathway [45]. Figures 3(e) and 3(f) showed that T-96 repressed the PI3K/AKT cell signaling pathway activity. To investigate whether the antitumor effect of T-96 was dependent on LSD1, we used siRNAs to knock down LSD1 expression, as shown in Figures 4(a) and 4(b), in LSD1-silenced SUM-1315 cells, the inhibitory effect of T-96 on
**Figure 4**: T-96 inhibited LSD1-mediated cell signal in the highly metastatic breast cancer cell SUM-1315. (a, b) LSD1 siRNA attenuated T-96 inhibited LSD1 pharmacological activity; (c, d) LSD1 inhibited CoREST/LSD1 protein-protein interaction by Co-IP assay. (e) Chemical structures of T-96; (f) the binding mode of T-96 bounded with the pocket of LSD1. Values are statistically significant at *P < 0.05.*
PTEN protein expression was attenuated. Further results from the coIP assay confirmed that T-96 attenuated the interaction between LSD1 and CoREST in Figures 4(c) and 4(d). These results indicated that LSD1 was required for T-96-induced antitumor effects in SUM-1315 cells.

### 3.4. In Silico Mode of Action Prediction for T-96

We docked T-96 onto a published crystal structure of the LSD1 (Figures 4(e) and 4(f)). The molecular docking predicted that the hydrogen bond formed between the phenolic hydroxy of T-96 and ARG316, which also contributed to the stable binding interaction in both complexes. This result indicated that T-96 processed powerful affinity toward LSD1 mainly through strong hydrogen bonding.

3.5. T-96-Induced antitumor Effects in Mice

Finally, we evaluated the antitumor efficacy of T-96 in vivo. In the xenograft model, SUM-1315 cells were inoculated subcutaneously into the BALB/c Nude mice. The mice were then treated by I.G with vehicle or T-96 (5 mg/kg/d) for 25 days. Compared with the vehicle-treated group, treatment with T-96 significantly decreased the growth of SUM-1315 xenograft (Figure 5(a)), reduced the volumes and weights of tumors (Figures 5(b) and 5(c)), and induced tumor death.

---

**Figure 5:** T-96-induced antitumor effects in mice. (a–d) T-96 inhibited SUM1315 cell proliferation in vivo; (e), T-96 induced SUM-1315 cells apoptosis by TUNEL; (f), T-96 decreased Ki-67 protein expression in SUM-1315 cells by immunofluorescence assay; (g and h) T-96 increased histone methylation by immunohistochemical assay; (i), T-96 increased PTEN protein expression in SUM-1315 cell by immunohistochemical assay. Values are statistically significant at *P* < 0.05.
Figure 5(d)). Figure 5(e) showed that in TUNEL assay, compared with the control group, the green fluorescence emitted by the cells increased in the T-96 group. And T-96 decreased Ki-67 protein expression in SUM1315 cells by immunofluorescence assay (Figure 5(f)). These results suggested that T-96 induced cancer cell apoptosis and inhibited proliferation. T-96 increased the methylation levels of Histone H3K4me2 and H3k9me2 and enhanced the protein expression of PTEN by immunohistochemical staining assay (Figures 5(g)–5(i)). Further analysis revealed that T-96 did not show significant toxicity on the body weights and tissue (Figure 6). These results demonstrated that T-96 exhibited potent anti-tumor activity in vivo.

4. Discussion

TNBC is much more aggressive than others and leads to a poorer prognosis. So, developing a new therapy for metastatic breast cancer or TNBC is an appealing concept. SUM-1315 is a highly metastatic and TNBC cell line. So, in this study SUM-1315 was employed to evaluate the antitumor activity of T-96 and to investigate the underlying
mechanisms in vitro. At the same time, the SUM-1315 xeno-graft model was used to evaluate the antitumor activity of T-96 in vivo.

Some articles have reported the inhibitory effect of T-96 on breast cancer and explored the mechanisms. ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport. The dysregulation of ARF1 expression and activity is involved in breast cancer. T-96 had the potential to inhibit ARF1 activity. T-96 could inhibit breast cancer proliferation via inhibiting hyperphosphorylation of pRB and its downstream pathway by targeting ARF1.

A previous study published by us found that T-96 could inhibit MDA-MB-231 (TNBC cells) migration, and suppress the expression of EMT-related genes and proteins. We found that the effect of T-96 inhibited invasion correlated with the mechanism by inhibiting both classical and non-classical TGF-β signaling pathways [27]. However, in these previous studies, they did not investigate the antitumor effect and mechanisms of T-96 from the perspective of affecting methylation. As shown in Figure 1, we demonstrated that T-96 was an antitumor adjuvant agent, which had shown antitumor activity on breast cancer cell lines. And T-96 had a more robust activity against SUM-1315, which was a highly metastatic and TNBC cell line and was characterized by the lowest response to chemotherapies and the worst outcome [47]. We found that T-96 showed poor antitumor activity on MCF-7, which is another breast cell line, not a TNBC cell line. And, as reported in Figure 1(a) and 2(a), T-96 exhibited a dose-dependent anti-proliferation effect against SUM-1315 cells. The members of the Bcl-2 family proteins are the hallmarks and regulators of the apoptotic process. Some Bcl-2 family members are located in the mitochondrial membrane, alter mitochondrial membrane permeability, trigger caspase activity, and determine the fate of the cells [45, 48]. And Bcl-2 family proteins are abnormally expressed in human breast cancer [49]. In SUM1315, T-96-induced apoptosis was associated with down-regulation of Bcl-2 and Bcl-xl expression, but upregulation of Bax expression in Figures 2(b) and 2(c).

PTEN, a kind of phosphatase, is found in almost all tissues of the human body. It modifies other proteins and fats (lipids) and removes phosphate groups from their substrates [50]. So, as a tumor suppressor, PTEN controls diverse cellular processes by protein posttranslational modifications. Some studies illustrated that there is tight crosstalk between PTEN and p53. PTEN could control the function of p53 by regulating p53 protein expression level and activity [45, 51]. Following, we detected the protein expression of PTEN, and found that T-96 significantly increased the amount of PTEN protein in Figures 3(a) and 3(b). PTEN could dephosphorylate phosphatidylinositols (3,4,5) triphosphate, a product of PI3K, and inactivate PI3K/AKT cell signaling pathway to suppress cell survival [52–54]. So, PTEN is an antagonist of the PI3K/AKT signaling pathway. And we found that
T-96 could also inhibit the phosphorylation of AKT (Figure 3(e), 3(f)). This result could further confirm the above observation.

LSD1, one member of the flavin-containing amine oxidase family and a part of transcriptional complexes, plays an important role in the regulation of transcription and gene expression [16, 55]. LSD1 is aberrantly overexpressed in a majority of cancers and has a significant correlation with aggressive pathological features and unfavorable prognosis [56–58]. Importantly, recent studies have illustrated inhibition of LSD1 activity or repression of LSD1 expression can inhibit tumor cell growth [59–62]. Many studies have focused on the role of LSD1 in breast cancer. They found that LSD1 was essential for breast cancer cell chemosensitivity, such as by coordinating with the SIN3A/HDAC complex and regulating a stem cell program [63, 64]. Moreover, LSD1 regulated ERα signaling in breast cancer, and inhibiting LSD1 induced significant growth arrest and apoptosis in the hormone-responsive breast cancer model [65]. And LSD1 activation promotes EMT programs in breast cancer [56]. So, most of these studies have focused on the inhibition of LSD1 to suppress invasion, metastasis, and EMT breast cancer [66–68]. Therefore, LSD1 is a therapeutic target in breast cancer therapy. In the present report, we found that T-96 could decrease the protein expression of LSD1 and increase the histone methylation of H3K9me2 and H3K9me2. Furthermore, T-96 could inhibit the protein expression of PTEN which was a direct target gene of LSD1 [44]. And knockdown of LSD1 gene expression by transfection of LSD1-specific siRNA could block the T-96-induced down-regulation of PTEN protein expression. CoREST, a functional corepressor required for the regulation of gene expression, could interact with LSD1 and enhance LSD1 demethylase activities toward H3K4 in vitro and in vivo [69, 70]. CoIP assay results showed that T-96 attenuated the interaction between LSD1 and CoREST. Moreover, the molecular docking assay further showed that T-96 processed powerful affinity toward LSD1 mainly interacting via hydrogen bonding. Altogether, these results indicated that restoration of LSD1 normal expression was necessary for T-96-induced antitumor activity.

Our data provide important information about the mechanisms of T-96 as a promising therapeutic agent, which effectively inhibited tumor cell growth and induced cancer cell apoptosis via LSD1-mediated epigenetic mechanisms. The specific mechanism of T-96 inducing tumor cells apoptosis is that T-96 could significantly decrease the protein expression of LSD1, increase its target protein PTEN expression and enhance histone methylation, and finally down-regulate the PI3K/AKT signaling pathway (Figure 7). Taken together, all these results demonstrate that LSD1 plays an important role in T-96-induced apoptosis in TNBC cells. Our findings suggest that T-96 deserves further investigation as a promising agent, because of the selective antitumor activity of T-96 to highly metastatic TNBC cells.

Abbreviations

T-96: Demethylzeylasteral
DMEM: Dulbecco’s Modified Eagle’s Medium
FBS: Fetal bovine serum
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling
LSD1: Lysine (K)-specific demethylase 1A
coIP assay: Coimmunoprecipitation assay
MTT assay: 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay
TNBC: Triple-negative breast cancer
EMT: Epithelial-to-mesenchymal transition
TWHF: Tripterygium wilfordii Hook F.

Data Availability

The data used to support the findings of this study are included within the article. Further information is available from the corresponding author upon request.

Conflicts of Interest

The authors have declared no conflicts of interest.

Authors’ Contributions

Zhengjie Shen, Yongjuan Gu, and Ruiyang Jiang contributed equally to this work.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China No.82104956, 82104939; the Natural Science Foundation of Jiangsu Province No. BK20190236.

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.
[2] J. Jin, Z. Tao, J. Cao, T. Li, and X. Hu, “DNA Damage Response Inhibitors: An Avenue for TNBC Treatment,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1875, no. 2, pp. 277–291, 2016.
[3] J. Y. So, J. Ohm, S. Lipkowitz, and L. Yang, “Triple Negative Breast Cancer (TNBC): Non-Genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Options,” Pharmacology & Therapeutics, vol. 237, article 108253, 2022.
[4] C.-Y. Yen, H.-W. Huang, C.-W. Shu et al., “DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers,” Cancer Letters, vol. 373, no. 2, pp. 185–192, 2016.
[5] Y. Li, “Modern epigenetics methods in biological research,” Methods, vol. 187, pp. 104–113, 2021.
[6] W. L. Tam and R. A. Weinberg, “The Epigenetics of Epithelial-Mesenchymal Plasticity in Cancer,” Nature Medicine, vol. 19, no. 11, pp. 1438–1449, 2013.
[7] Y. Chen, B. Ren, J. Yang et al., “The role of histone methylation in the development of digestive cancers: a potential direction
for cancer management,” *Signal Transduction and Targeted Therapy*, vol. 5, no. 1, p. 143, 2020.

[8] X. Gao, Q. Chen, H. Yao et al., “Epigenetics in Alzheimer’s Disease,” *Frontiers in Aging Neuroscience*, vol. 14, 2022.

[9] M. Rosa-Garrido, D. J. Chapski, and T. M. Vondriska, “Epigenomes in cardiovascular disease,” *Circulation Research*, vol. 122, no. 11, pp. 1586–1607, 2018.

[10] R. A. Copeland, M. E. Solomon, and V. M. Richon, “Protein methyltransferases as a target class for drug discovery,” *Nature Reviews Drug Discovery*, vol. 8, no. 9, pp. 724–732, 2009.

[11] E. L. Greer and S. Yang, “Histone methylation: a dynamic mark in health, disease and inheritance,” *Nature Reviews Genetics*, vol. 13, no. 5, pp. 343–357, 2012.

[12] A. Hosseini and S. Minucci, “A comprehensive review of lysine-specific demethylase 1 and its roles in cancer,” *Epigenetics*, vol. 9, no. 8, pp. 1113–1142, 2017.

[13] J. Taylor-Papadimitriou and J. M. Burchell, “Histone methylases and demethylases regulating antagonistic methyl marks: changes occurring in cancer,” *Cell*, vol. 11, no. 7, p. 1113, 2022.

[14] J. Carnesecchi, C. Force, L. Zhang et al., “ERR Induces H3K9 Demethylation by LSD1 to Promote Cell Invasion,” *Proceedings of the National Academy of Sciences*, vol. 114, no. 15, pp. 3909–3914, 2017.

[15] C. Martinez-Gamero, S. Malla, and F. Agullo, “LSD1: expanding functions in stem cells and differentiation,” *Cell*, vol. 10, no. 11, p. 3252, 2021.

[16] D. Kim, K. I. Kim, and S. H. Baek, “Roles of Lysine-Specific Demethylase 1 (LSD1) in Homeostasis and Diseases,” *Journal of Biomedical Science*, vol. 28, no. 1, p. 41, 2021.

[17] S. Hayami, J. D. Kelly, H. S. Cho et al., “Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers,” *International Journal of Cancer*, vol. 128, no. 3, pp. 574–586, 2011.

[18] G.-J. Yang, P.-M. Lei, S.-Y. Wong, D.-L. Ma, and C.-H. Leung, “Pharmacological inhibition of LSD1 for cancer Treatment,” *Molecules*, vol. 23, no. 12, pp. 3194, 2018.

[19] S. Ambrosio, C. D. Saccà, and B. Majello, “Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A,” *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, vol. 1860, no. 9, pp. 905–910, 2017.

[20] Y. Fang, G. Liao, and Y. Bin, “LSD1/KDM1A Inhibitors in Clinical Trials: Advances and Prospects,” *Journal of Hematology & Oncology*, vol. 12, no. 1, p. 129, 2019.

[21] X. Zhang, X. Wang, T. Wu et al., “Therapeutic potential of targeting LSD1/KDM1A in cancers,” *Pharmacological Research*, vol. 175, article 105958, 2022.

[22] T. Tamaki, A. Kawamura, Y. Komatsu, H. Kawamura, H. Maruyama, and T. Morota, “Phenolic nortriterpene from *Tripterygium wilfordii* Hook F,” *Journal of Visualized Experiments*, vol. 16, no. 119, 2021.

[23] Q. Wang, Y. Xiao, T. Liu, H. Yuan, and C. Li, “Demethylzeylasteral ameliorates inflammation in a rat model of unilateral ureteral obstruction through inhibiting activation of the NF-κB pathway,” *Molecular Medicine Reports*, vol. 16, no. 1, pp. 373–379, 2017.

[24] Y. Yu, B. Yong, C. Xu, and L. Zhang, “T-96 Attenuates Inflammation by Inhibiting NF-κB in Adjuvant-Induced Arthritis,” *Frontiers in bioscience (Landmark edition)*, vol. 25, no. 3, pp. 498–512, 2020.

[25] F. Wang, X. Tian, Z. Zhang et al., “Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways,” *International Journal of Cancer*, vol. 142, no. 9, pp. 1938–1951, 2018.

[26] L. Pan, F. Feng, J. Wu et al., “Demethylzeylasteral Targets Lactate by Inhibiting Histone Lactylation to Suppress the Tumorigenicity of Liver Cancer Stem Cells,” *Pharmacological Research*, vol. 181, article 106270, 2022.

[27] L. Li, Y. Ji, J. Fan et al., “Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways,” *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 392, no. 5, pp. 593–603, 2019.

[28] J. Wang, M. Li, X. Han et al., “MiR-1976 knockout promotes epithelial-mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis,” *Cell Death & Disease*, vol. 11, no. 7, 2020.

[29] A. Ammazzalorso, M. Gallorini, M. Fantacuzzi et al., “Design, Synthesis and Biological Evaluation of Imidazole and Triazole-Based Carbamates as Novel Aromatase Inhibitors,” *European Journal of Medicinal Chemistry*, vol. 211, article 113115, 2021.

[30] G. Lu and Y. Zhang, “MicroRNA-340-5p Suppresses Non-Small Cell Lung Cancer Cell Growth and Metastasis by Targeting ZNF503,” *Cellular & Molecular Biology Letters*, vol. 24, no. 1, p. 34, 2019.

[31] L. Di Francesco, A. Verrico, I. A. Asteriti et al., “Visualization of Human Karyopherin Beta-1/Importin Beta-1 Interactions with Protein Partners in Mitotic Cells by Co-Immunoprecipitation and Proximity Ligation Assays,” *Scientific Reports*, vol. 8, no. 1, p. 1850, 2018.

[32] X. Zhu, A. Zelmer, and S. Wellmann, “Visualization of Protein-protein Interaction in Nuclear and Cytoplasmic Fractions by Co-immunoprecipitation and *in situ* Proximity Ligation Assay,” *Journal of Visualized Experiments*, vol. 16, no. 119, 2017.

[33] M. Swets, A. Wouters, D. Krijgsmans et al., “HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and Western blot analysis: its expression characteristics remain enigmatic,” *Clinical Immunology*, vol. 194, pp. 80–86, 2018.

[34] M. Tonogai, S. M. Nakayama, Y. Ikenaka et al., “Bioimaging of Pb and STIM1 in Mice Liver, Kidney and Brain Using Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) and Immunohistochemistry,” *Chemosphere*, vol. 238, article 124581, 2020.

[35] Y. Zhang, A. C. Daquing, F. Amaya-Manzanares, O. Sirin, C. Tseng, and M. G. Kolonin, “Stromal progenitor cells from endogenous adipose tissue contribute to Pericytes and adipocytes that populate the tumor Microenvironment,” *Cancers*, vol. 7, no. 20, pp. 5198–5208, 2015.

[36] L. Pirolo, O. Ciesielski, and A. Balcerczyk, “The methylation status of the epigene: its emerging role in the regulation of tumor angiogenesis and tumor growth, and potential for drug targeting,” *Cancers*, vol. 10, no. 8, p. 268, 2018.

[37] K. Zhang, J. Wang, L. Yang et al., “Targeting Histone Methyltransferase G9a Inhibits Growth and Wnt Signaling Pathway by Epigenetically Regulating HP1α and APC2 Gene Expression in Non-Small Cell Lung Cancer,” *Molecular Cancer*, vol. 17, no. 1, p. 153, 2018.
[38] L. Yu, F. Ye, Y. Y. Li et al., "Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1/CDK6 Axis," *Carcinogenesis*, vol. 41, no. 5, pp. 678–688, 2020.

[39] M. T. McCabe, H. P. Mohammad, O. Barbash, and R. G. Kru-ger, "Targeting histone methylation in cancer," *Cancer Journal*, vol. 23, no. 5, pp. 292–301, 2017.

[40] Y.-i. Tsukada, J. Fang, H. Erdjument-Bromage et al., "Histone demethylation by a family of Jumji domain-containing proteins," *Nature*, vol. 439, no. 7078, pp. 811–816, 2006.

[41] A. Maiques-Diaz and T. C. P. Somervaille, "LSD1: Biologic Roles and Therapeutic Targeting," *Epigenomics*, vol. 8, no. 8, pp. 1103–1116, 2016.

[42] S. Lim, A. Janzer, A. Becker et al., "Lysine-Specific Demethylase 1 (LSD1) is HighlyExpressed in ER-negative Breast Cancers and a Biomarker Predicting Aggressive Biology," *Carcinogenesis*, vol. 31, no. 3, pp. 512–520, 2010.

[43] Y. Yu, B. Wang, K. Zhang et al., "High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma," *Biochemical and Biophysical Research Communications*, vol. 437, no. 2, pp. 192–198, 2013.

[44] A. Yokoyama, K. Igarashi, T. Sato et al., "Identification of myel- lin transcription factor 1 (MyT1) as a subunit of the neural cell type-specific lysine-specific demethylase 1 (LSD1) complex," *Journal of Biological Chemistry*, vol. 289, no. 26, pp. 18152–18162, 2014.

[45] A. Carracedo and P. P. Pandolfo, "The PTEN-PI3K pathway: of feedbacks and cross-talks," *Oncogene*, vol. 27, no. 41, pp. 5527–5541, 2008.

[46] J. Chang, R. Yang, L. Chen et al., "Discovery of ARF1-targeting Inhibitor Demethylzyelasteral as a Potential Agent Against Breast Cancer," *Acta Pharmacologica Sinica B*, vol. 12, no. 5, pp. 2619–2622, 2022.

[47] A. Gajan, A. Sarma, S. Kim, K. Gurdziel, G. S. Wu, and M. P. Shekhar, "Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells," *Frontiers in Oncology*, vol. 11, 2021.

[48] J.-C. Martinou and R. I. Youle, "Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics," *Developmental Cell*, vol. 21, no. 1, pp. 92–101, 2011.

[49] F. Vaillant, D. Merino, L. Lee et al., "Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer," *Cancer Cell*, vol. 24, no. 1, pp. 120–129, 2013.

[50] B. D. Hopkins and R. E. Parsons, "Molecular pathways: intercel- lular PTEN and the potential of PTEN restoration therapy," *Clinical Cancer Research*, vol. 20, no. 21, pp. 5379–5383, 2014.

[51] Y.-R. Lee, M. Chen, and P. P. Pandolfo, "The functions and reg- ulation of the PTEN tumour suppressor: new modes and pros- pects," *Nature Reviews. Molecular Cell Biology*, vol. 19, no. 9, pp. 547–562, 2018.

[52] J. O. Lee, H. Yang, M. M. Georgescu et al., "Crystal structure of the PTEN tumour suppressor: implications for its phospho-no-sitide phosphatase activity and membrane association," *Cell*, vol. 99, no. 3, pp. 323–334, 1999.

[53] D. Cristofano, "The multiple roles of PTEN in tumor suppress- ion," *Cell*, vol. 100, no. 4, pp. 387–390, 2000.

[54] Y. Yin and W. H. Shen, "PTEN: a new guardian of the genome," *Oncogene*, vol. 27, no. 41, pp. 5443–5453, 2008.

[55] V. D. Nair, Y. Ge, N. Balasubramaniam et al., "Involvement of histone demethylase LSD1 in short-time-scale gene expression changes during cell cycle progression in embryonic stem cells," *Molecular and Cellular Biology*, vol. 32, no. 23, pp. 4861–4876, 2012.

[56] T. Boulding, R. D. McCuiga, A. Tan et al., "LSD1 Activation Promotes Inducible EMT Programs and Modulates the Tumour Microenvironment in Breast Cancer," *Scientific Reports*, vol. 8, no. 1, p. 73, 2018.

[57] S. A. Miller, R. A. Policastro, S. Sriramkumar et al., "LSD1 and aberrant DNA methylation mediate persistence of Enteroendocrine progenitors that SupportBRAF-mutant colorectal cancer," *Cancer Research*, vol. 81, no. 14, pp. 3791–3805, 2021.

[58] J. Ding, Z.-M. Zhang, Y. Xia et al., "LSD1-mediated Epigenetic Modification Contributes to Proliferation and Metastasis of Colon Cancer," *British Journal of Cancer*, vol. 109, no. 4, pp. 994–1003, 2013.

[59] C. Lee, V. A. Rudneva, S. Erkek et al., "Lsd1 as a Therapeutic Target in Gfi1-activated Medulloblastoma," *Nature Communications*, vol. 10, no. 1, 2019.

[60] S. Xu, X. Wang, Y. Yang, Y. Li, and S. Wu, "LSD1 Silencing Contributes to Enhanced Efficacy of anti-CD47/PD-L1 Immuno- therapy in Cervical Cancer," *Cell Death & Disease*, vol. 12, no. 4, 2021.

[61] S. Zhang, M. Liu, Y. Yao, B. Yu, and H. Liu, "Targeting LSD1 for Acute Myeloid Leukemia (AML) Treatment," *Pharmacological Research*, vol. 164, article 105335, 2021.

[62] E. M. Nguyen, H. Taniguchi, J. M. Chan et al., "Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC," *Journal of Thoracic Oncology*, vol. 17, no. 8, pp. 1014–1031, 2022.

[63] Y. Yang, W. Huang, R. Qiu et al., "LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemo- therapy in breast cancer," *Journal of Molecular Cell Biology*, vol. 10, no. 4, pp. 285–301, 2018.

[64] J. Verigos, P. Karakaikolas, D. Kordias et al., "The Histone Demethylase LSD1/MDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program," *Cancers*, vol. 11, no. 10, p. 1585, 2019.

[65] R. Benedetti, C. Dell’Aversana, T. De Marchi et al., "Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Sig- naling in Breast Cancer," *Cancers*, vol. 11, no. 12, p. 2027, 2019.

[66] Z. Gong, A. Li, J. Ding et al., "OTUD7B Deubiquitinates LSD1 to Govern its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis," *Advanced Science*, vol. 8, no. 15, article 2004504, 2021.

[67] J. Liu, J. Feng, L. Li et al., "Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer," *EMBO Reports*, vol. 21, no. 2, article e85937, 2020.

[68] X. Hu, D. Xiang, Y. Xie et al., "LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression," *Oncogene*, vol. 38, no. 44, pp. 7017–7034, 2019.

[69] Y. Wang, H. Zhang, Y. Chen et al., "LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer," *Cell*, vol. 138, no. 4, pp. 660–672, 2009.

[70] Y. J. Shi, C. Matson, F. Lan, S. Iwase, T. Baba, and Y. Shi, "Regulation of LSD1 Histone Demethylase Activity by its Associ- ated Factors," *Molecular Cell*, vol. 19, no. 6, pp. 857–864, 2005.